Investigational drug · Phase 2
DM002
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 7, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "DM002"
First trial start
2025
Feb 17, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DM002", any sponsor or status.
Conditions studied
As listed on its trial records.
- Ovarian Neoplasms
- Prostatic Neoplasms
- Endometrial Neoplasms
- Colorectal Neoplasms
- Solid Carcinoma
- Pancreatic Cancer
Approved drugs for the same conditions: Pancreatic cancer · Endometrial cancer · Oncology · Kidney and urology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "DM002" as an intervention, largest first.
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.Industry
NCT06751329 · 280 participants (planned) · Start Feb 17, 2025 · Primary completion Oct 8, 2027
Drug: DM002 · For: Ovarian Neoplasms; Prostatic Neoplasms; Endometrial Neoplasms and 3 more
Sites: San Francisco, California; Huntersville, North Carolina; Oklahoma City, Oklahoma · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Ovarian Neoplasms
- Anlotinib hydrochlorideAL3818, CatequentenibPhase 312 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Alveolar Soft Part Sarcoma, Metastatic Colorectal Cancer, Endometrial Neoplasms
- R-DXdDS 6000a, MK-5909Phase 310 trials
Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- Mocertatug rezetecanMo-RezPhase 36 trials
GSK · Ovarian Neoplasms, Neoplasms, Endometrial, Tumours, Gynecological
- OlomorasibLY3537982Phase 36 trials
Eli Lilly · Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Neoplasm Metastasis
- AL58805Phase 22 trials
Advenchen Pharmaceuticals, LLC. · Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
- BMX-001Phase 21 trial
BioMimetix JV, LLC · Ovarian Neoplasms, Endometrial Cancer, Endometrial Neoplasm
- VB15010Phase 21 trial
Zhejiang Yangli Pharmaceutical Technology Co., Ltd. · Cancer, Neoplasms, Neoplasms, Breast
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.